DMP Stock Overview
Manufactures and sells off-patent branded pharmaceutical products in Germany.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 3/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
Dermapharm Holding SE Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €33.35 |
52 Week High | €43.22 |
52 Week Low | €30.80 |
Beta | 1.11 |
11 Month Change | -1.91% |
3 Month Change | -7.36% |
1 Year Change | -15.57% |
33 Year Change | -60.01% |
5 Year Change | -2.13% |
Change since IPO | 28.27% |
Recent News & Updates
Dermapharm Holding SE Beat Revenue Forecasts By 6.7%: Here's What Analysts Are Forecasting Next
Aug 31Dermapharm Holding SE's (ETR:DMP) P/E Still Appears To Be Reasonable
Aug 17It Looks Like Dermapharm Holding SE's (ETR:DMP) CEO May Expect Their Salary To Be Put Under The Microscope
Jun 21Recent updates
Dermapharm Holding SE Beat Revenue Forecasts By 6.7%: Here's What Analysts Are Forecasting Next
Aug 31Dermapharm Holding SE's (ETR:DMP) P/E Still Appears To Be Reasonable
Aug 17It Looks Like Dermapharm Holding SE's (ETR:DMP) CEO May Expect Their Salary To Be Put Under The Microscope
Jun 21These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Extensively
Apr 29Dermapharm Holding SE's (ETR:DMP) Price In Tune With Earnings
Feb 07Dermapharm Holding (ETR:DMP) Seems To Use Debt Quite Sensibly
Dec 15An Intrinsic Calculation For Dermapharm Holding SE (ETR:DMP) Suggests It's 24% Undervalued
Nov 17Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet
Aug 28Dermapharm Holding SE's (ETR:DMP) Intrinsic Value Is Potentially 76% Above Its Share Price
Aug 01Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet
May 29Is Dermapharm Holding SE (ETR:DMP) Trading At A 44% Discount?
May 03Dermapharm Holding's (ETR:DMP) Soft Earnings Are Actually Better Than They Appear
Apr 04We Think Dermapharm Holding (ETR:DMP) Can Stay On Top Of Its Debt
Feb 22Is Dermapharm Holding (ETR:DMP) A Risky Investment?
Nov 17Is Dermapharm Holding (ETR:DMP) A Risky Investment?
Aug 16Is Dermapharm Holding (ETR:DMP) A Risky Investment?
May 18Is Dermapharm Holding (ETR:DMP) Using Too Much Debt?
Feb 17These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Reasonably Well
Nov 19Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?
Aug 21Is Dermapharm Holding SE (ETR:DMP) Trading At A 28% Discount?
Jul 31Is Dermapharm Holding SE (ETR:DMP) The Right Choice For A Smart Dividend Investor?
May 03Calculating The Intrinsic Value Of Dermapharm Holding SE (ETR:DMP)
Apr 16Here's Why Dermapharm Holding (ETR:DMP) Can Manage Its Debt Responsibly
Mar 25Did You Miss Dermapharm Holding's (ETR:DMP) Impressive 110% Share Price Gain?
Mar 07Is Dermapharm Holding SE's (ETR:DMP) 27% ROE Better Than Average?
Feb 15Something To Consider Before Buying Dermapharm Holding SE (ETR:DMP) For The 1.4% Dividend
Jan 29Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?
Dec 24The Dermapharm Holding (ETR:DMP) Share Price Has Gained 45% And Shareholders Are Hoping For More
Dec 07Dermapharm Holding SE Just Missed Earnings - But Analysts Have Updated Their Models
Nov 18Shareholder Returns
DMP | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -4.2% | -4.0% | 1.0% |
1Y | -15.6% | -15.0% | 11.2% |
Return vs Industry: DMP matched the German Pharmaceuticals industry which returned -15% over the past year.
Return vs Market: DMP underperformed the German Market which returned 11.2% over the past year.
Price Volatility
DMP volatility | |
---|---|
DMP Average Weekly Movement | 3.4% |
Pharmaceuticals Industry Average Movement | 5.1% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 11.6% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DMP has not had significant price volatility in the past 3 months.
Volatility Over Time: DMP's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1991 | 3,603 | Hans-Georg Feldmeier | ir.dermapharm.de |
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany. The company operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals.
Dermapharm Holding SE Fundamentals Summary
DMP fundamental statistics | |
---|---|
Market cap | €1.80b |
Earnings (TTM) | €83.04m |
Revenue (TTM) | €1.15b |
21.6x
P/E Ratio1.6x
P/S RatioIs DMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DMP income statement (TTM) | |
---|---|
Revenue | €1.15b |
Cost of Revenue | €433.72m |
Gross Profit | €712.97m |
Other Expenses | €629.94m |
Earnings | €83.04m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 14, 2024
Earnings per share (EPS) | 1.54 |
Gross Margin | 62.18% |
Net Profit Margin | 7.24% |
Debt/Equity Ratio | 190.5% |
How did DMP perform over the long term?
See historical performance and comparison